Shattuck Labs, Inc. (STTK)
4.595
-0.06
(-1.39%)
USD |
NASDAQ |
Nov 17, 16:00
4.45
-0.14
(-3.16%)
After-Hours: 20:00
Shattuck Labs Enterprise Value : 280.68M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 280.68M |
| November 13, 2026 | 279.67M |
| November 12, 2026 | 295.96M |
| November 11, 2026 | 320.40M |
| November 10, 2026 | 300.03M |
| November 09, 2026 | 314.29M |
| November 06, 2026 | 276.61M |
| November 05, 2026 | 263.37M |
| November 04, 2026 | 330.58M |
| November 03, 2026 | 363.17M |
| November 02, 2026 | 347.89M |
| October 30, 2026 | 372.33M |
| October 29, 2026 | 388.63M |
| October 28, 2026 | 397.28M |
| October 27, 2026 | 393.72M |
| October 26, 2026 | 370.30M |
| October 23, 2026 | 365.21M |
| October 22, 2026 | 376.41M |
| October 21, 2026 | 374.37M |
| October 20, 2026 | 400.85M |
| October 19, 2026 | 352.99M |
| October 16, 2026 | 358.08M |
| October 15, 2026 | 369.28M |
| October 14, 2026 | 348.91M |
| October 13, 2026 | 365.21M |
| Date | Value |
|---|---|
| October 12, 2026 | 426.31M |
| October 09, 2026 | 414.09M |
| October 08, 2026 | 382.52M |
| October 07, 2026 | 382.01M |
| October 06, 2026 | 402.88M |
| October 05, 2026 | 468.06M |
| October 02, 2026 | 491.48M |
| October 01, 2026 | 502.68M |
| September 30, 2026 | 500.64M |
| September 29, 2026 | 453.12M |
| September 28, 2026 | 442.04M |
| September 25, 2026 | 405.78M |
| September 24, 2026 | 429.95M |
| September 23, 2026 | 434.99M |
| September 22, 2026 | 449.09M |
| September 21, 2026 | 409.81M |
| September 18, 2026 | 399.73M |
| September 17, 2026 | 383.62M |
| September 16, 2026 | 386.64M |
| September 15, 2026 | 395.71M |
| September 14, 2026 | 418.87M |
| September 11, 2026 | 418.87M |
| September 10, 2026 | 413.84M |
| September 09, 2026 | 431.97M |
| September 08, 2026 | 449.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Nektar Therapeutics | 761.05M |
| Protagonist Therapeutics, Inc. | 7.349B |
| ACADIA Pharmaceuticals, Inc. | 2.321B |
| Alnylam Pharmaceuticals, Inc. | 20.79B |
| Anika Therapeutics, Inc. | 154.24M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.20M |
| Total Expenses (Quarterly) | 25.20M |
| EPS Diluted (Quarterly) | -0.1376 |
| Earnings Yield | -11.04% |
| Normalized Earnings Yield | -11.03 |